Navigation Links
Par Pharmaceutical Begins Shipment of KHEDEZLA (desvenlafaxine) Extended-release Tablets, 50 mg and 100 mg
Date:9/23/2013

WOODCLIFF LAKE, N.J., Sept. 23, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has begun shipping KHEDEZLA (desvenlafaxine) Extended-release (ER) Tablets, 50 mg and 100 mg.  Par's development partner, Osmotica Pharmaceutical Corp., received approval for its New Drug Application (NDA) for KHEDEZLA ER Tablets from the U.S. Food and Drug Administration pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.  KHEDEZLA is indicated for the treatment of major depressive disorder (MDD).  KHEDEZLA provides patients and physicians with additional options in the treatment of major depressive disorder. 

Osmotica's NDA included comparative bioequivalence testing against Pfizer's PRISTIQ® (desvenlafaxine) Extended-Release Tablets. KHEDEZLA is not generically substitutable for PRISTIQ 50 mg and 100 mg tablets. According to IMS Health data, annual U.S. sales of PRISTIQ are approximately $614 million. 

Under terms of its agreement with Osmotica, Par will market, sell and distribute KHEDEZLA in the United States. Par will share profits from the sales of the product with its development partner.  

Important Information about KHEDEZLA ER Tablets 
A black box warning is associated with this product regarding increased risk of suicidal thoughts and behaviors in children, adolescents and young adults taking antidepressants.  All persons taking KHEDEZLA should be monitored for worsening and emergence of suicidal thoughts and behaviors.  KHEDEZLA is not approved for use in pediatric patients. Refer to full prescribing information for complete boxed warning.

KHEDEZLA (desvenlafaxine) Extended-release Tablets are contraindicated in patients who are hypersensitive to desvenlafaxine succinate, venlafaxine hydrochloride or to any component of the product.  Angioedema has been reported in patients treated with desvenlafaxine.

The use of MAOIs intended to treat psychiatric disorders with KHEDEZLA or within 7 days of stopping treatment with KHEDEZLA is contraindicated because of an increased risk of serotonin syndrome.  The use of KHEDEZLA within 14 days of stopping a MAOI intended to treat psychiatric disorders is also contraindicated.  Starting KHEDEZLA in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome.

About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals.  For press release and other company information, visit www.parpharm.com.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Immune Pharmaceuticals Inc. Trading Symbol is Now IMNP on Both NASDAQ OMX Stockholm Exchange and OTCQX Trading Platform
3. Isis Pharmaceuticals to Conduct Webcast and Conference Call to Discuss ISIS-APOCIII Rx Phase 2 Data
4. Harwood Feffer LLP Announces Investigation of Transcept Pharmaceuticals, Inc.
5. New Pharmaceutical Product Launch Spend: Developing Competitive Launch and Pre-launch Budgets to Ensure a Successful Market Entry
6. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
7. Auxilium Pharmaceuticals, Inc. Raises $50 Million In Additional Financing
8. Thomson Reuters Reveals New Strategies for Navigating Big Data in the Pharmaceutical Industry
9. Rafarma Pharmaceuticals, Inc. (RAFA) announces plans for PCAOB-Registrant Audit and Streamlining of Corporate Structure to Upgrade Market Listing.
10. Legal Actions, Quarterly Dividends, Collaborations, and New Appointments - Research Report on Johnson & Johnson, Zoetis, Abbott, Teva Pharmaceuticals, and Baxter
11. Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgens Acquisition of Onyx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016 Dehaier Medical Systems ... the "Company"), which develops, markets and sells medical ... China and international markets, today ... aims to concentrate the Company,s resources to develop ... business and to focus more on its major ...
(Date:2/5/2016)... Site Profile: --> Site ... People, announced their latest primary healthcare case study where speech recognition ... and to save the practice money. Site Profile: ... Challenge: --> ,- Wirral CCG ,- VoicePower client since ... Wirral CCG ,- VoicePower client since 2013 Challenge: ...
(Date:2/4/2016)... 2016  Edwards Lifesciences Corporation (NYSE: EW ), ... disease and critical care monitoring, announced today that it ... with Morgan Stanley & Co. LLC to repurchase $325 ... of the Company,s previously authorized program to repurchase up ... --> --> Under ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is ... to provide the most effective tattoo removal today, Dr. Bentkover is the only doctor ... by Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) ...
(Date:2/5/2016)... ... ... Colorize is a web theme package created exclusively for Final ... dynamic moving camera. Colorize is perfect for personal and web related videos and its ... to 5 focus points per scene, stage floor scene presets that are great for ...
(Date:2/5/2016)... ... 2016 , ... Health and wellness is a topic that should concern all ... are experiencing an illness. Migraines are a severe form of a headache and often ... not wish the pain on their worst enemy, the feeling can last for many ...
(Date:2/5/2016)... Ramsey, NJ (PRWEB) , ... February 05, 2016 ... ... Optimizing Primary Care for Patients with Rare Diseases, a continuing medical education (CME) ... conference is the first of its kind—and a first for ACCORD, whose mission ...
(Date:2/5/2016)... ... February 05, 2016 , ... KICVentures ( http://www.kicventures.com ... Development event in New York City on Thursday, January 21, 2016. Kingsley ... Mediacom, (both alumnus of the varsity Columbia soccer program) spoke at the event, ...
Breaking Medicine News(10 mins):